Giving Life to Science®

We're advancing scientific breakthroughs to patients. Our R&D engine has yielded new medicines for devastating diseases including inflammatory, fibrotic & immunological conditions, intractable cancers & lymphatic, neurological & GI disorders

Focus on the Brain Immune Gut (BIG) Axis

25 therapeutics and therapeutic candidates

16 are clinical stage

2 granted FDA clearance & European marketing authorization

Relationships with leading pharma companies or their investment arms

Team of world-class scientists and industry leaders

PureTech's Components of Value


Learn more about our unique discovery process

Wholly Owned Pipeline

Our programs*
Phase 1
Phase 2
Phase 3
IPF & potentially other PF-ILDs
Long COVID2 respiratory complications & related sequelae
Lymphatic flow disorders, including lymphedema
Anti-Galectin-9 MAb
Solid tumors
Anti-Delta-1 MAb
Solid tumors
Oral Allopregnanolone
Neurological indications
Oral IL-22 +
(Imbrium collaboration) Non-opioid
Phase completedPhase in progressRegistration-enabling development plans in progress

Cash at Parent Level

Founded Entities

Internal Pipeline
PureTech's Lymphatic Leap
Gamma Delta T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation

CD4(+) T regulatory cells (T(regs)), which express the Foxp3 transcription factor, play a critical role in the maintenance of immune homeostasis. Here, we show that in mice, T(regs) were most abundant in the colonic mucosa.

Full Article

Science: The Gut’s Clostridium Cocktail
Press releases
PureTech Announces Publication of New Preclinical Research from Collaborators that Supports Mesenteric Lymphatic Dysfunction as a Potential Cause of and Therapeutic Target for Obesity and Insulin Resistance
Press releases
PureTech to Present at Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
Press releases
PureTech Founded Entity Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia

1 The FDA and corresponding regulatory authorities will ultimately review our clinical results and determine whether our wholly-owned therapeutic candidates are safe and effective. No regulatory agency has made any such determination that our wholly-owned therapeutic candidates are safe or effective for use by the general public for any indication.

2 Long COVID is a term being used to describe the emerging and persistent complications following the resolution of COVID-19 infection, also known as post-acute COVID-19 syndrome (PACS).

3 Funding figure includes private equity financings, loans and promissory notes, public offerings or grant awards. Funding figure excludes future milestone considerations received in conjunction with partnerships and collaborations such as those with Boehringer Ingelheim, Imbrium Therapeutics L.P., Shionogi & Co., Ltd. or Eli Lilly. Calculated as of January 1, 2017 to June 30, 2021. 

4 This represents a non-IFRS number.  For a reconciliation of this number to IFRS, please see below:

Consolidated Cash Reserves is a non IFRS-measure which consists of cash, cash equivalents and short-term investments held at PureTech Health plc and consolidated subsidiaries. PureTech Level Cash Reserves is a non-IFRS measure which consists of cash, cash equivalents and short-term investments held at PureTech Health plc and only wholly-owned subsidiaries. PureTech Level Cash and Cash Equivalents is a non-IFRS measure which consists of cash and cash equivalents held at PureTech Health plc and only wholly-owned subsidiaries.